Novartis’ Entresto could lead the charge on an impressive uptick in growth for the heart failure treatment space, according to a new analysis from research and consulting firm GlobalData. The report predicts the market value for these treatments will go from $3.7 billion in 2016 to an estimated $16.1 billion by 2026 signifying an increase…